Dubai, 18th June 2014.
Invivoscribe Technologies, Inc. (San Diego, CA, USA) signed an exclusive master distribution agreement with the Alliance Global Group (Dubai, UAE) to bring Invivoscribe Technologies personalized molecular diagnosticsto AGBL’s markets.
“Modern advancement in personalized medicine relies on determining a patients’ genetic makeup, which plays a critical role in diagnosis, prognosis, and treatment. With Invivoscribe technologies, we can provide physicians and cancer centers with access to clinically-validated personalized molecular diagnostics”, says Hala Al-Taher, Molecular Biology Product Specialist at Alliance Global Group. “A simple test can transform patient’s life for the better, saving them an unsatisfactory and painful experience. Using Invivoscribe’s CE-marked IVD products, physicians can be confident they prescribe the right medication to the right patients.” Al-Taher added.
Invivoscribe’s manufactured CE-marked IVD products are used to identify, classify and monitor leukemias, lymphomas and other lymphoproliferative diseases. The company also has CLIA- and CAP-accredited clinical reference laboratories in the EU and USA that are licensed to perform FLT3 biomarker testing. These are the only laboratories in the world licensed to determine the mutation status of both FLT3 and NPM1.